ACHV

ACHIEVE LIFE SCIENCES, INC.

In Vitro & In Vivo Diagnostic Substances · SIC 2835CIK 949858Held by 1 tracked managerEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

—

Net Income FY2025

$(55.0M)

EPS (Basic, as reported)

$-1.25

Net Margin FY2025

—

ROE FY2025

-254.0%

Total Equity

$22.0M

Shares Out

103M

Business description

ACHIEVE LIFE SCIENCES, INC. — In Vitro & In Vivo Diagnostic Substances. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2009–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 0 → 0

Fiscal yearFY2016FY2017FY2018FY2019FY2020⚑FY2021FY2022⚑FY2023⚑FY2024FY2025

Revenue——00——————

Research & development(15)(3)(6)(10)(7)(24)(30)(16)(23)—

General & administrative(9)(4)(7)(7)(8)(9)(11)(11)(16)—

Total operating expenses(26)(7)(13)(17)(15)(33)(41)(27)(39)(55)

Interest expense——————(2)(3)(2)(1)

Interest & investment income0000000121

Other income (expense), net1(7)0000(2)(3)(1)0

Pre-tax income(2)(14)(13)(16)(15)(33)(42)(30)(40)(55)

Income tax expense0—————————

Net income(20)(11)(13)(16)(15)(33)(42)(30)(40)(55)

EPS — basic————($5.42)($4.08)($4.00)($1.50)($1.24)($1.25)

EPS — diluted————($5.42)($4.08)($4.00)($1.50)($1.24)($1.25)

Shares outstanding — basic (M)————3811203244

Shares outstanding — diluted (M)————3811203244

Showing the latest 10 of 17 fiscal years.

⚑ Weighted-average shares changed ×2.67 between FY2020 and FY2021 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×1.82 between FY2022 and FY2023 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×1.60 between FY2023 and FY2024 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.